Skip to main content

Table 3 Antibiotic sensitivity of the multi-drug resistant gram negative isolates

From: Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study

Organisms Pip/Taz Imepenem Polymyxin B Gentamycin Amikacin Aztreonam Ceftriaxone Ceftazidime Ofloxacin Cefuroxime Amp/clav Tobramycin
Acinetobacter Species 0/12 0/12 12/12 0/12 0/12 0/6 0/12 0/12 0/12 0/8 0/2 6/9
(0%) (0%) (100%) (0%) (0%) (0%) (0%) (0%) (0%) (0%) (0%) (66.6%)
Klebsiella Pneumoniae 5/8 6/8 3/3 0/8 3/8 0/8 0/8 0/2 2/8 0/7 2/7  
(62.5%) (75%) (100%) (0%) (37.5%) (0%) (0%) (0%) (25%) (0%) (28.6%)  
Pseudomonas Aeruginosa 3/5 1/6 5/5 1/6 2/6 ¼ 0/3 2/4 1/6 0/2 -- 0/1
(60%) (16.7%) (100%) (16.7%) (33.3%) (25%) (0%) (50%) (16.7%) (0%)   (0%)
Escherichia Coli 5/7 7/7 -- 5/7 7/7 0/7 0/7 0/1 4/7 0/6 3/7 --
(71.5%) (100%)   (71.5%) (100%) (0%) (0%) (0%) (57.2%) (0%) (42.8%)  
Enterobacter Species ¾ 4/4 -- 1/5 1/5 0/4 0/4 0/1 ¼ 0/4 ¼ --
(75%) (100%)   (20%) (20%) (0%) (0%) (0%) (25%) (0%) (25%)  
Stenotrophomonas Maltophilia ½ -- -- 0/1 0/1 0/2 0/2 ½ ¾ -- -- --
(50%)    (0%) (0%) (0%) (0%) (50%) (75%)    
Burkholderia Cepacia -- ½ -- -- -- -- -- 2/2 2/2 -- -- --
  (50%)       (100%) (100%)    
Pseudomonas Species ½ 2/3 3/3 1/3 1/3 0/3 0/3 0/1 1/3 0/1 -- 0/1
(50%) (66.6%) (100%) (33.3%) (33.3%) (0%) (0%) (0%) (33.3%) (0%)   (0%)
n (%) 18/40 21/42 23/23 8/42 14/42 1/34 0/39 5/25 14/46 0/28 6/20 6/11
(45%) (50%) (100%) (19.1%) (35.8%) (3%) (0%) (40%) (30.5%) (0%) (30%) (54.6%)
  1. Pip/Taz = Piperacillin/Tazobactem Amp/Clav = Ampicillin + Clavulanic acid.